Celcuity Inc. Common Stock (CELC)

FairStock Score: 11/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-style investor, I start with the business, not the story. Celcuity is a clinical-stage biotech with 155 employees, no reported revenue in the filed periods, and a lead candidate, Gedatolisib, aimed at solid tumors. That may be promising science, but I see no durable competitive moat yet: there is no reported revenue and the lead candidate is still in development. The financials are those of a cash-consuming enterprise. Celcuity lost $63.8 million in FY2023, $111.8 million in FY2024, and $177.0 million in FY2025. In fiscal Q1 2026, the quarter ended 2026-03-31, it lost $52.8 million; in fiscal Q2 2026, the quarter ended 2026-06-30, it lost $78.9 million, versus a $45.3 million loss in fiscal Q2 2025. Trailing free cash flow is negative $192.3 million, a FairStock-calculated FCF yield of -6.2%. The balance sheet carries a debt-to-equity ratio of 3.20, and FairStock's ROE is -1433.70%. Valuation offers no Graham margin of safety: at the 2026-10-13 close of $63.19, the market cap is about $3.1 billion, with a P/B of 66.19 and a P/E of -14.70. The Piotroski F-Score is 0/9, Altman Z-Score 2.22, FairStock Score 11/100, and the computed Lynch category is none because it lost money in each of the last four years. The price depends almost entirely on future drug success, not on current numbers. I would call the business weak today, the moat unproven, and the price expensive relative to what is actually being earned.

In plain English: Celcuity is a small drug developer working on a targeted cancer treatment. It has no reported product revenue, has lost money every year, and is burning cash. At $63.19 on 2026-10-13, the $3.1 billion price looks expensive compared with the current numbers, because the value depends on future drug success rather than today's business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer